株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

ウロキナーゼの中国市場

Investigation Report on China's Urokinase Market, 2019-2023

発行 China Research and Intelligence 商品コード 337515
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.13円で換算しております。
Back to Top
ウロキナーゼの中国市場 Investigation Report on China's Urokinase Market, 2019-2023
出版日: 2019年08月20日 ページ情報: 英文 30 Pages
概要

当レポートでは、中国におけるウロキナーゼの特許および承認状況、売上・販売量の推移と予測 (過去・今後5年間分)、価格動向、主な製薬会社とその市場シェア、競合環境とその展望、主要メーカーのプロファイルなどを提供しています。

第1章 ウロキナーゼの関連概念

  • ウロキナーゼの効能
  • 中国におけるウロキナーゼ市場の動向
  • 中国でのウロキナーゼの特許取得・政府認証の動き

第2章 中国国内のウロキナーゼの販売動向

  • ウロキナーゼの販売額
  • ウロキナーゼの販売量
  • ウロキナーゼの販売量:剤型別 (過去5年間分)

第3章 中国の主要なウロキナーゼ・メーカーの分析

  • 主要メーカーの市場シェアの分析
  • Nanjing Nanda Pharmaceutical Co., Ltd.
  • Tianjin Biochemical Pharmaceutical Co., Ltd.
  • Livzon Pharmaceutical Factory of Livzon Group
  • Wuhan Humanwell Pharmaceutical Co., Ltd.
  • Shandong PKU High-tech Huatai Pharmaceutical Co., Ltd.

第4章 中国国内のウロキナーゼの価格

  • Nanjing Nanda Pharmaceutical Co., Ltd.
  • Tianjin Biochemical Pharmaceutical Co., Ltd.
  • Livzon Pharmaceutical Factory of Livzon Group
  • Wuhan Humanwell Pharmaceutical Co., Ltd.
  • Shandong PKU High-tech Huatai Pharmaceutical Co., Ltd.

第5章 中国のウロキナーゼ市場の将来展望

  • 中国のウロキナーゼ市場を左右する要因
    • 市場促進要因と市場機会
    • 脅威と課題
  • 市場規模の予測 (今後5年間分)
  • 市場動向の予測
目次
Product Code: 1908397

Description

Thrombolytic therapy is using drugs to dissolve thrombi and achieve revascularization so that the brain tissue of the blocked vascular perfusion area can regain blood oxygen. As fibrin is an important composition of thrombus, current thrombolytic therapy mainly use drugs such as Streptokinase, Urokinase and Tissue Plasminogen Activator (t-PA) to dissolve fibrin.

Thrombolytic drugs include three generations. The first generation is non-specific plasminogen activators such as Streptokinase and Urokinase; the second generation is represented by t-PA such as Alteplase and Prourokinase; the third generation includes Reteplase, Tenecteplase, Nateplase, Recombinant Human Urokinase, etc.

Although Urokinase is a thrombolytic drug of the first generation, it is widely used in China. It is an enzyme protein isolated from healthy human urine or cultured from human kidney tissue.

Urokinase acts directly on the endogenous fibrinolytic system. It can catalyze the cracking of plasminogen to plasmin which dissolves thrombi by degrading fibrin clots as well as the fibrinogen, coagulation factors V and VIII in blood circulation. With a rapid onset and good effect on newly formed thrombi, Urokinase can also increase the vascular enzymatic activity of adenosine diphosphate (ADP), inhibit ADP-induced platelet aggregation and prevent thrombosis. After intravenous infusion, the activity of plasmin in the patient will be significantly increased; after a few hours of drug withdrawal, the activity of plasmin will be restored. As a traditional thrombolytic drug that has been marketed in China for many areas, Urokinase is widely used to treat acute myocardial infarction, cerebral thrombosis, pulmonary vein thrombosis, lower extremity vein thrombosis and other forms of vascular thrombosis.

Economic development, aging population and unhealthy diet push up the incidence of thrombotic diseases in China, which boosts the demand for Urokinase. According to CRI's market survey, in 2017, the sales value of Urokinase in China reached CNY 50.56 million, representing a CAGR of 7.90% from 2013 to 2017. The Urokinase by Nanjing Nanda Pharmaceutical Co., Ltd. took up the largest market share in China. Its market share was about 50.60% by sales value and about 38.50% by sales volume.

It is expected that the market size of Urokinase in China will continue to grow in the next few years.

Topics covered:

  • Market size of Urokinase in China
  • Competitive landscape of China's Urokinase market
  • Prices of Urokinase in China
  • Favorable and unfavorable factors influencing China's Urokinase market
  • Prospect of China's Urokinase market

Table of Contents

1 Relevant Concepts of Urokinase

  • 1.1 Indications for Urokinase
  • 1.2 Development of Urokinase in China
  • 1.3 Patents and Government Approval on Urokinase in China

2 Sales of Urokinase in China, 2013-2017

  • 2.1 Sales Value of Urokinase
  • 2.2 Sales Volume of Urokinase
  • 2.3 Sales of Urokinase by Dosage Form in China, 2013-2017

3 Analysis on Major Urokinase Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Urokinase Manufacturers
  • 3.2 Nanjing Nanda Pharmaceutical Co., Ltd.
  • 3.3 Tianjin Biochemical Pharmaceutical Co., Ltd.
  • 3.4 Livzon Pharmaceutical Factory of Livzon Group
  • 3.5 Wuhan Humanwell Pharmaceutical Co., Ltd.
  • 3.6 Shandong PKU High-tech Huatai Pharmaceutical Co., Ltd.

4 Prices of Urokinase in China, 2017-2018

  • 4.1 Nanjing Nanda Pharmaceutical Co., Ltd.
  • 4.2 Tianjin Biochemical Pharmaceutical Co., Ltd.
  • 4.3 Livzon Pharmaceutical Factory of Livzon Group
  • 4.4 Wuhan Humanwell Pharmaceutical Co., Ltd.
  • 4.5 Shandong PKU High-tech Huatai Pharmaceutical Co., Ltd.

5 Prospect of China's Urokinase Market, 2019-2023

  • 5.1 Factors Influencing China's Urokinase Market
    • 5.1.1 Driving Forces and Market Opportunities
    • 5.1.2 Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

Selected Charts

  • Chart Sales of Urokinase in China, 2013-2017
  • Chart Sales Value of Urokinase in Parts of China, 2013-2017
  • Chart Sales Volume of Urokinase in China, 2013-2017
  • Chart Sales Volume of Urokinase in Parts of China, 2013-2017
  • Chart Sales Value of Urokinase Injections in China, 2013-2017
  • Chart Sales Volume of Urokinase Injections in China, 2013-2017
  • Chart Market Share of Top 5 Urokinase Manufacturers by Sales Value in China, 2013-2017
  • Chart Market Share of Top 5 Urokinase Manufacturers by Sales Volume in China, 2013-2017
  • Chart Sales Value of Urokinase by Nanjing Nanda Pharmaceutical Co., Ltd., 2013-2017
  • Chart Sales Volume of Urokinase by Nanjing Nanda Pharmaceutical Co., Ltd., 2013-2017
  • Chart Sales Value of Urokinase by Livzon Pharmaceutical Factory of Livzon Group, 2013-2017
  • Chart Sales Value of Urokinase by Wuhan Humanwell Pharmaceutical Co., Ltd., 2013-2017
  • Chart Sales Value of Urokinase by Shandong PKU High-tech Huatai Pharmaceutical Co., Ltd., 2013-2017
  • Chart Prices of Urokinase by Nanjing Nanda Pharmaceutical Co., Ltd. in Parts of China, 2017-2018
  • Chart Prices of Urokinase by Tianjin Biochemical Pharmaceutical Co., Ltd. in Parts of China, 2017-2018
  • Chart Prices of Urokinase by Livzon Pharmaceutical Factory of Livzon Group in Parts of China, 2017
Back to Top